EUCTR2011-005384-24-DE进行中（未招募）不适用
TACTT1 - TACTT1
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A subject will be eligible for inclusion in this study if all of the following criteria apply:
- •1. Persistent tinnitus (unilateral or bilateral) following acute acoustic trauma, acute otitis media, middle ear surgery or inner ear barotraumas with onset up to three months ago (i.e. acute tinnitus), as documented by medical report.
- •2. Age = 18 years and = 65 years.
- •3. Negative pregnancy test for women of childbearing potential.
- •4. Willing and able to attend the study visits.
- •5.Able to read and understand study documents, and investigator instructions.
- •6. Signed IEC (Independent Ethics Committee)-approved Informed Consent Form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 72
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1. Fluctuating Tinnitus.
- •2. Intermittent Tinnitus.
- •3. Menière's Disease.
- •4. Ongoing acute or chronic Otitis media or Otitis externa.
- •5. Any drug-based therapy for Otitis media that is ongoing or was performed in the past 2 weeks.
- •6. Any therapy known as potentially Tinnitus-inducing (e.g. aminoglycosides, cisplatin, loop diuretics, high doses of aspirin [> 5 adult doses/day] or quinine) in the past 2 weeks or that is ongoing or planned for the study duration.
- •7. Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 2 weeks, e.g. prednisolone, dexamethasone, pentoxyfilline, betahistine, diazepam, car-bamazepine, sodium valproate and antidepressants.
- •8. Use of any other NMDA receptor antagonist (e.g. memantine, dextromethorphan) in the past 2 weeks, or that is ongoing, or that is planned for the study duration.
- •9. Any ongoing or planned treatment of Tinnitus for the study duration.
- •10. History within the past two years or presence of drug abuse or alcoholism.
- •11. Any clinically relevant respiratory, cardiovascular, neurological (except vertigo), or psychiatric disorder, as determined by the Investigator.
- •12. Known hypersensitivity, allergy or intolerance to the study medication or any history of severe, abnormal drug reaction.
- •13. Women who are breast-feeding, pregnant or who are planning to become pregnant during the trial.
- •14. Women of childbearing potential who are unwilling or unable to practice contraception, such as hormonal contraceptives, double barrier, sexual abstinence or intercourse with a partner who has been vasectomised for at least three months.
- •15. Concurrent participation in another clinical trial or participation in another clinical trial within 30 days prior to study entry.
研究者
相似试验
进行中（未招募）
1 期
Administration of a single dose or of three doses of AM-101to patients with Tinnitus (Ringing in the Ears) and comparision of both doses.EUCTR2011-005384-24-BEAuris Medical AG72
进行中（未招募）
不适用
/ACerebral venous thrombosisEUCTR2010-020302-15-PTIMM - Instituto de Medicina Molecular164
招募中
1 期
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid TumorsCTIS2022-500849-24-00Tolremo Therapeutics AG25
招募中
1 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumoursCTIS2023-504199-19-00T3 Pharmaceuticals AG100
招募中
1 期
Safety and Tolerability of AC01 in patients with heart failureMedDRA version: 20.0Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541Heart FailureCTIS2022-500347-20-00Anacardio AB116